Across commercial insurance, Medicare, and Medicaid populations, oncology is the top category of spend, and the drug pipeline has increasing specific and complex therapies.
Oncology is a safe bet as the top spend category for the next few years, said Sneha Sharma, PharmD, director, specialty clinical solutions, Magellan Rx, said in Las Vegas during the Asembia Specialty Pharmacy Summit, held May 2-5.
During her presentation, Sharma ran through the trends in the commercial, Medicare, and Medicaid populations, and oncology was the top spend category in all 3. Starting with commercial, she noted that oncology trends approximately 15% higher in per-member per-month (PMPM) spend than other categories.
“This keeps in line with the trend that oncology is becoming its own entity,” Sharma said.
The top 5 categories of spend in commercial were oncology, biologic drugs for autoimmune disorders (BDAIDs; eg, Crohn disease, ulcerative colitis), multiple sclerosis, ophthalmic injections, and asthma/chronic obstructive pulmonary disease.
Overall, the top 5 categories made up 70% of the medical benefit PMPM, with oncology making up 46% on its own.
In the Medicare population, oncology is again the top spend and utilization category, and the PMPM between oncology and all other therapies differs by as much as 35%. The COVID-19 lockdowns and stay-at-home orders had a bigger impact on oncology claims in this population compared with the commercial population, Sharma noted.
The top 5 categories of spend in Medicare were oncology, followed by ophthalmic injections, hematology, bone resorption inhibitors, and BDAIDs. These 5 categories made up 80% of the medical benefit PMPM, with oncology making up 59% alone.
Finally, looking at the Medicaid space, Sharma noted the varying patient trends and needs. “With the influx of unemployment and economic upheaval that we saw due to COVID, Medicaid saw some large increases in their medical benefit PMPM spend at about a 7% increase in PMPM,” she said.
There was a little variation in the top 5 categories of spend, although oncology was still at the top. The other 4 were BDAIDs, rare diseases, multiple sclerosis, and immune globulin. These top 5 categories made up 62% of the medical benefit PMPM, and oncology made up 37% alone.
Sharma noted that while there were variabilities across lines of business, oncology was the exception. However, oncology utilization was down 4.8% in commercial, 9.3% in Medicare, and 13.8% in Medicaid compared with prepandemic levels in 2019.
Looking ahead at the drug pipeline, Sharma focused on gene therapies and oncology drugs because these categories will continue to drive spend. “Payers are most concerned with the trend in oncology and impact of gene therapy,” she said. “These 2 high-cost, high-impact categories have robust pipelines and unique management requirements.”
Among the drugs she highlighted in the pipeline were:
“Drugs within our gene therapy and oncology pipelines are becoming more specific, somewhat complicated, and fulfilling needs in patient populations where standard nonspecific therapies or no therapies have existed,” Sharma said. “We must continue to evaluate and manage these trends with programs that we know are working or continue to find informative strategies for high-cost specialty drugs.”
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen